<DOC>
	<DOCNO>NCT01221103</DOCNO>
	<brief_summary>The rationale study design base fact maximum tolerate dose ( MTD ) single-agent ofatumumab bendamustine previously determine . The choice dose combination base investigator unpublished clinical experience , well inferred extensive experimental data use monoclonal antibody combination chemotherapy lymphoma patient . The start dose 2 main component drug MTD drug single agent .</brief_summary>
	<brief_title>Dexamethasone , Ofatumumab Bendamustine ( DOT ) First-line Mantle-cell Lymphoma ( MCL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Age ≥ 60 year . 2 . ECOG Performance Status 01 . 3 . Life expectancy least 6 month . 4 . Histological diagnosis MCL ( morphology , CD5+/CD20+ /CD23 , ( 11:14 ) and/or cyclin D1 overexpression ) . 5 . Disease require treatment ( patient bone marrow disease , candidate watchandwait approach , exclude ) 6 . Adequate bone marrow , liver renal function , unless abnormality relate tumor unlikely affect safety bendamustine ofatumumab use . Adequate marrow organ function assess follow laboratory requirement conduct within 7 day prior screen : Hemoglobin ≥ 9.0 g/dL Absolute neutrophil count ( ANC ) ≥ 1000/µl Platelet count ≥ 75000/µl Total bilirubin ≤ 1.5 time ULN AST ALT ≤ 2.5 x ULN Alkaline phosphatase ≤ 4 x ULN Serum creatinine ≤ 2.5 x ULN 7 . PTINR/PTT &lt; 1.5 x ULN [ Patients therapeutically anticoagulated agent coumadin heparin allow participate provide prior evidence underlie abnormality parameter exist ] 8 . Written informed consent . 1 . Previous treatment mantlecell lymphoma ( MCL ) 2 . Chronic current infectious disease require systemic antibiotic , antifungal , antiviral treatment , limited , chronic renal infection , chronic chest infection bronchiectasis , tuberculosis active Hepatitis C. 3 . Other past current malignancy . Subjects free malignancy least 5 year , history completely resect nonmelanoma skin cancer , successfully treat situ carcinoma eligible . 4 . Clinically significant cardiac disease include unstable angina , acute myocardial infarction within 6 month prior Visit 1 , congestive heart failure , arrhythmia require therapy , exception extra systole minor conduction abnormalities 5 . History significant cerebrovascular disease event significant symptom sequelae 6 . Glucocorticoid use , unless give dos ≤ 100 mg/day hydrocortisone ( equivalent dose glucocorticoid ) &lt; 7 day exacerbation CLL ( e.g. , asthma ) 7 . Known HIV positive 8 . Subjects current active hepatic biliary disease ( exception patient Gilbert 's syndrome , asymptomatic gallstone , liver metastasis stable chronic liver disease per investigator assessment ) . 9 . Positive serology Hepatitis B ( HB ) define positive test HBsAg . In addition , negative HBsAg HBcAb positive HBsAb negative , HB DNA test perform positive subject exclude . Note : If HBcAb positive HBsAb positive , indicative past infection , subject include . 10 . Positive serology hepatitis C ( HC ) define positive test HCAb , case reflexively perform HC RIBA immunoblot assay sample confirm result . 11 . Treatment known nonmarketed drug substance experimental therapy within 5 terminal half live 4 week prior Visit 1 , whichever longer currently participate interventional clinical study 12 . Known suspected inability comply study protocol 13 . History organ allograft 14 . Patients evidence history bleed diathesis . 15 . Patients undergoing renal dialysis . 16 . Substance abuse , medical psychological social condition may interfere patient 's participation study evaluation study result . 17 . Any condition unstable could jeopardize safety patient compliance study .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Dexamethasone</keyword>
	<keyword>Ofatumumab</keyword>
	<keyword>Bendamustine</keyword>
	<keyword>Lymphoma , Mantle-Cell</keyword>
	<keyword>Non-Hodgkin lymphoma</keyword>
</DOC>